Quest Diagnostics Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)0.71 Intrinsic Value $158.26median of 6 methods · middle span $142-$326based on filings through 30 Jun 2026 Market Price $231.09Price as of 1 Oct 2026 OvervaluedIntrinsic value is 32% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $25.5B Enterprise Value $30.5B Shares Outstanding 112M diluted Moat Rating Narrow Next Earnings Date22 Oct 2026 Next ex-dividend6 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Quest entered the second half of 2026 with strong operating momentum: second-quarter revenue rose 10.2%, organic growth was 10.0%, and adjusted diluted EPS increased 19.1%. Management raised full-year revenue and adjusted-EPS guidance, while advanced diagnostics and consumer channels continued expanding. Offsetting these positives, revenue per requisition declined 2.8% and adjusted operating margin narrowed to 16.5% from 16.9%. The shares closed at $242.76 on August 28, close to their $247.19 52-week high. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$204.00 Mean target$245.87 High · most bullish analyst$265.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $204.0018% Persistent reimbursement or mix pressure deepens the decline in revenue per requisition, while integration and operating costs prevent volume growth from translating into margin expansion. Performance falling below the lower ends of the raised revenue or adjusted-EPS guidance would materially weaken the thesis. Base CaseCentral scenario $245.8758% Matches the consensus meanQuest delivers within its raised 2026 guidance, with strong requisition and organic revenue growth offset partly by lower revenue per requisition and modest margin pressure. This preserves earnings growth but offers a balanced risk-reward profile from the August 28 market price. Bull CaseUpside scenario $265.0024% Sustained organic demand, double-digit growth in advanced diagnostics, continued consumer-channel expansion, and successful commercialization of newer Alzheimer's and oncology tests could keep revenue and adjusted EPS near or above the upper ends of management's 2026 guidance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |